Reported 3 days ago
Henry Schein Inc. (HSIC), a global healthcare product distributor, has seen underperformance with its stock down 2.3% over the past year compared to a 13.7% rise in the S&P 500. Despite a strong Q2 2025 revenue of $3.2 billion, shares fell 7.4% following an earnings miss due to decreased U.S. dental product demand. Analysts' consensus rating is 'Hold,' with a mix of ratings and a mean price target of $72.23, indicating a slight upside potential.
Source: YAHOO